Candidate urine biomarker discovery from only five pairs of samples before and after tumor resection in glioma patients
Introduction
Gliomas are the most common primary brain tumor in adults, representing 81% of malignant brain tumors [1] . Malignant gliomas have a very poor prognosis and a high risk of tumor recurrence after treatment. Therefore, timely diagnosis of gliomas and glioma patient monitoring for disease recurrence are essential to improve patient survival. There are no currently generally accepted screening protocols to reveal asymptomatic brain tumors [2] . Thus, there is an urgent need to discover new biomarkers for noninvasive diagnosis and to monitor tumor recurrence in glioma patients.
Urine is a sensitive biofluid for biomarker research. Without the control of homeostatic mechanisms, urine accumulates systemic bodily changes and thus is an excellent biomarker source [3] . A roadmap for the urine biomarker era was previously proposed [4] , and many candidate urine biomarkers were successfully identified in animal models [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In these animal models, the effects of genetic and environmental factors on the urine proteome were limited to the minimum, which is useful when identifying disease biomarkers. However, patient urine can be affected by many factors, including gender, age, exercise, and hormone conditions [16] ; thus, many clinical samples are required to identify verifiable disease biomarkers. A self-controlled study should be able to avoid the interferences of individual differences among patients. It is unknown whether promising biomarkers can be identified from the relatively smaller number of glioma patient urine samples before and after tumor resection.
In this study, urine samples from five glioma patients were collected at the time of tumor diagnosis and after total surgical removal of brain tumors. Postoperative urine samples were collected 1-2 weeks after surgery and just before discharge to avoid trauma effects from altering the urine proteome. A comparative proteomic analysis of urine samples before and after tumor resection was performed using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).
Materials and Methods

Patients
Patients were recruited from the Peking University International Hospital. All patients had evident tumors identified in magnetic resonance imaging (MRI) studies at preoperative urine collection. The final tumor diagnosis was based on the histopathology of resected tissues. None of the cancer patients were treated with chemotherapeutic agents or radiation during sample collection. None of the adult patients had known histories of vascular malformation or recent surgery. The gross total resection of brain tumors was also documented by imaging.
All subjects were informed about the purpose of the study and signed informed consent forms before study inclusion. The study was approved by the local ethical committee of Peking University International Hospital.
Urine collection and sample preparation
Midstream first morning urine was collected from five glioma patients before and after tumor resection. The preoperative urine samples were collected from patients one day before surgery. The postoperative samples were collected 1-2 weeks after the patient recovered from surgery to avoid effects from stress. After collection, urine samples were centrifuged at 5,000 g for 30 min at 4°C to remove cell debris and contaminants. The supernatant was precipitated with three volumes of ethanol at -20°C overnight followed by centrifugation at 12,000 g for 30 min. The pellet was resuspended in lysis buffer (8 M urea, 2 M thiourea, 50 mM Tris, and 25 mM DTT).
The protein concentration of each sample was measured using the Bradford assay.
Tryptic digestion
Urinary proteins were prepared using the FASP method. Protein samples (100 µg) were denatured with 20 mM dithiothreitol at 37°C for 1 h and alkylated with 50 mM iodoacetamide in the dark for 30 min. The samples were loaded onto 10 kD filter devices (Pall, Port Washington, NY, USA) and centrifuged at 14,000 g and 18°C.
After washing twice with UA (8 M urea in 0.1 M Tris-HCl, pH 8.5) and four times with 25 mM NH 4 HCO 3 , the samples were digested with trypsin (enzyme-to-protein ratio of 1:50) at 37°C overnight. The peptide mixtures were desalted using Oasis HLB cartridges (Waters, Milford, MA) and dried by vacuum evaporation.
LC-MS/MS analysis
Ten peptide samples resulting from the above digestion were re-dissolved in 0.1% formic acid to 0.5 µg/µL. For analysis, 1 µg of peptides from an individual sample was loaded onto a trap column and separated on a reverse-phase C18 column (75 µm × 100 mm, 2 µm) using the EASY-nLC 1200 HPLC system (Thermo Fisher To identify more urinary proteins and validate the differential proteins identified above, the ten peptide samples were reanalyzed using a 90 min elution time, keeping the other MS parameters the same as above.
Label-free proteome quantification
The proteomic data were searched against the SwissProt Human database (released in 2017 and containing 20,169 entries) using Mascot software (version 2.6.1, Matrix Science, London, UK). The parent ion tolerance was set to 10 ppm, and the fragment ion mass tolerance was set to 0.05 Da. Carbamidomethyl cysteine was set as a fixed modification, and the oxidation of methionine was considered a variable modification.
The specificity of trypsin digestion was set for cleavage after K or R, and two missed trypsin cleavage sites were allowed. Peptide and protein identification was further validated using Scaffold software (version 4.8.4, Proteome Software Inc., Portland, OR). Peptide identifications were accepted at an FDR less than 1.0% using the Scaffold Local FDR algorithm and with at least 2 unique peptides. Comparisons across different samples were performed after normalization to total spectra accounts using Scaffold software. Spectral counting was used to compare the protein abundance between two groups according to a previously described procedure [17, 18] .
Statistical analysis
Statistical analysis was performed with SPSS. Comparisons between the two groups were conducted using paired Student's t-test. Group differences resulting in P-values < 0.05 were considered statistically significant.
Results
Clinical characteristics of glioma patients
A total of 5 consecutive and histopathology diagnosed glioma patients were recruited 
Changes to the urine proteome after tumor resection
Ten urine samples from five glioma patients before and after tumor resection were collected, and label-free LC-MS/MS quantification was used to characterize the differential expression of urinary proteins. A total of 1,377 urinary proteins with at least two unique peptides were identified with < 1% FDR at the protein level. All identification and quantification details are presented in Table S1 .
From the spectral counts of the identified proteins, there were significant individual differences between glioma patient samples. Urine samples were divided into a patient group and treatment group, which indicated the condition of glioma patients before or after tumor resection. Differential proteins were screened with the following criteria: fold change ≥ 1.5 between two groups and P-value of paired t-test < 0.05. All five patient samples indicated similar changes in protein level after surgical treatment.
A total of 27 differential proteins were identified; their details are described in Table 2 .
Of these 27 proteins, the eight most significant were Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), mitochondrial 10-kDa heat shock protein (HSPE1), adhesion G protein-coupled receptor F5 (ADGRF5), mitochondrial malate dehydrogenase (MDH2), intestinal maltase-glucoamylase (MGAM), acid ceramidase (ASAH1), calreticulin (CALR), and thrombospondin-4 (THBS4) (Figure 2) .
After reviewing the Human Protein Atlas Database available from www.proteinatlas.org, we discovered that 20 of these proteins are detectable in human glioma tissues using antibodies. These proteins might be secreted by glioma tissues and released into urine.
Functional analysis of differential urinary proteins
Functional annotation of the differential proteins was performed using DAVID, and they were classified as biological process, molecular function, molecular components and pathways. In the biological process category, regulation of tissue remodeling, autophagy, negative regulation of gene expression, positive regulation of natural killer cell-mediated cytotoxicity and angiogenesis were overrepresented (Figure 3) . In the cellular component category, the majority of the identified proteins were extracellular exosome, lysosome, extracellular space and membrane proteins. In the molecular function category, peptide binding, integrin binding and metalloaminopeptidase activity were overrepresented. To identify the major biological pathways represented in the differential urinary proteins, KEGG was used for canonical pathway enrichment analysis. The pathways for the lysosome, the renin-angiotensin system, the phagosome and folate biosynthesis were significantly enriched.
Additionally, a total of 10 proteins were related to neurological diseases, including annexin A7, carboxypeptidase, vitellogenic-like, cathepsin D, crystallin alpha B, gamma-glutamyl hydrolase, lysosomal-associated membrane protein 1, nectin cell adhesion molecule 2, programmed cell death 1 ligand 2, quinoid dihydropteridine reductase, and thrombospondin 4.
Validation of differential urinary proteins
To identify more urinary proteins and validate altered protein level, the ten peptide samples were reanalyzed with an extended elution time of 90 min. A total of 1,652 urinary proteins were identified in this proteomic analysis (Table S2) . Of the 27 proteins identified above, 17 proteins were verified to have significantly different levels in this analysis ( Table 2 ).
Discussion
In this study, a comparative proteomic analysis of urine samples from five glioma patients before and after tumor resection was performed using label-free proteome quantification. After brain tumor removal, the levels of 27 urinary proteins was significantly changed. Among these proteins, the abundance of 23 proteins was significantly increased after tumor removal, and four proteins were significantly decreased.
Of the differential urinary proteins, several have been previously associated with gliomas in previous studies, such as CEACAM1, ANXA7, CALR, CRYAB, CD276
antigen, pIgR, cathepsin D, beta-glucuronidase, and acid ceramidase ( Table 2) . For example, CEACAM1 controls matrix metalloproteinase-9 (MMP-9) secretion by neutrophils [19] , and MMP-9 was reported to be a candidate brain cancer biomarker [2] . CEACAM1 silencing inhibits cell proliferation and promotes apoptosis in human glioma cells, suggesting that CEACAM1 is a potential glioma therapy target [20] .
ANXA7 is a tumor suppressor gene. ANXA7 protein expression decreased in glioma tissues, and ANXA7 degradation might contribute to glioma progression [21] .
Furthermore, loss of ANXA7 is associated with glioblastoma patient prognosis, and its expression was a strong predictor of patient outcome [22, 23] . CALR has also been implicated in cancer. Lower CALR levels are observed in glioma tissues than in normal brain tissues, and its expression is correlated with glioma tumor grade and patient survival [24] . Alpha-crystallin B chain (CRYAB) is an anti-apoptotic protein [25] . In glioblastoma multiforme (GBM), CRYAB levels were reportedly elevated [26] , and CRYAB knockdown increased invasiveness in glioma cells [27] . CD276 antigen has been reported to be upregulated in high-grade glioma [28] . Its expression correlates with malignancy grade in gliomas and with poor patient survival [29] .
Expression of polymeric immunoglobulin receptor (pIgR) was identified as a novel predictor of poor glioma patient prognosis after surgical resection [30] . Additionally, cathepsin D was identified as an important protein related to glioma invasion [31] . β -glucuronidase is an enzyme found in the necrotic area of GBM [32] . Acid ceramidase is a novel drug target for adjuvant pediatric brain tumor therapies [33] .
Collectively, these urinary proteins might serve as noninvasive biomarker candidates to detect gliomas. Because these proteins were identified by comparing glioma patient samples before and after tumor resection, these proteins have potential clinical applications for diagnosing the presence of cancer and to monitor tumor recurrence after treatment in glioma patients.
Autophagy is involved in tumorigenesis, and a blockade has been proposed as an alternative therapeutic option. Autophagy is reportedly enhanced in astrocytomas compared to that in normal brain tissue [34] . In our study, autophagy was a significantly enriched biological process according to bioinformatics analyses, and four candidate proteins were involved in this process, including cathepsin D, lysosome-associated membrane glycoprotein 1, lysosome-associated membrane glycoprotein 2 and annexin A7.
Gliomas are characterized by abundant capillary angiogenesis [35] , and antiangiogenic therapy is a promising approach to treat malignant gliomas [36] . In our study, several proteins were identified that are relevant to angiogenesis, such as CEACAM1 [37] , CD276 [38] , aminopeptidase N [39] and thrombospondin-4 [40] .
Interestingly, thrombospondin-1 is involved in glioma pathogenesis and is a potential therapeutic target [41] , but whether thrombospondin-4 plays a similar role requires further study.
Urine has been largely ignored during biomarker discovery for brain diseases compared to other bodily fluids, such as cerebrospinal fluid (CSF) and blood.
However, few urinary-based biomarker studies examining brain diseases provided evidence that urine is a good source for relevant biomarkers [2, 42] . In this study, although a small number of clinical samples were analyzed, we identified several candidate biomarker proteins previously associated with gliomas in clinical studies.
These proteins are likely to be validated in a large-scale urine sample analysis of glioma patients. As a preliminary study, our results show great potential for urine biomarker development to monitor gliomas or other brain cancers. However, a larger number of clinical urine samples from patients are needed to verify the specific proteins and protein patterns with clinical applications as noninvasive biomarkers for disease diagnosis and/or monitoring of tumor recurrence.
Conclusion
Using label-free proteome quantification, candidate urinary biomarkers were Table S1 . Proteome profiling of glioma patient urine samples. 
